The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Pirtobrutinib shows efficacy in BTKi refractory Waldenström’s macroglobulinemia patients
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses results from the Phase I/II BRUIN trial (NCT03740529), which is evaluating pirtobrutinib, a highly selective, non-covalent Bruton’s tyrosine kinase inhibitor (BTKi) in patients with several B-cell malignancies. In this video, Dr Cheah reports on the cohort of patients with Waldenström’s macroglobulinemia (WM) who are both naïve and refractory to covalent BTKis. In the 80 WM patients analyzed, 63 were previously exposed to a covalent BTKi, and the overall response rate (ORR) was 67%, with 23% achieving complete remission (CR) and very good partial response (VGPR). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Beigene: Consultancy, Honoraria; TG Therapeutics: Consultancy, Honoraria; Eli Lilly and Company: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria; Merck Sharp & Dohme: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding.
